Tag: hla antibody screening industry

  • Human Leukocyte Antigen (HLA) Antibody Screening Market Forecast To Reach $1.47 Billion By 2030: Key Trends Explained

    Human Leukocyte Antigen (HLA) Antibody Screening Market Forecast To Reach $1.47 Billion By 2030: Key Trends Explained

    Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

    Human Leukocyte Antigen (HLA) Antibody Screening Market Growth Potential: How Will Market Size Shift Through 2030?

    The human leukocyte antigen (HLA) antibody screening market has experienced substantial growth in its size over recent years. This market is projected to expand from $0.98 billion in 2025 to $1.06 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. Historically, this expansion can be linked to several factors, including an escalating number of organ transplant operations, a higher occurrence of end-stage organ failure, enhanced understanding of transplant rejection dangers, the broadening scope of transfusion medicine practices, and advancements in immunoassay platform technology.

    The human leukocyte antigen (HLA) antibody screening market is expected to experience significant expansion in the coming years. Its valuation is projected to reach $1.47 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period is driven by factors such as the increasing need for precise transplant matching, the wider adoption of multiplex bead-based assays, rising investments in transplant immunology research, the broadening of transplant programs in developing markets, and technological advancements in automated HLA antibody screening systems. Dominant trends during this period include the growing utilization of single antigen bead assays for superior sensitivity, an increasing demand for thorough pre-transplant immunological risk assessments, the expanded application of high-throughput flow cytometry in HLA screening, the development of post-transplant antibody monitoring protocols, and enhanced standardization of HLA antibody detection methodologies.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=72197599&type=smp&name=Human%20Leukocyte%20Antigen%20%28HLA%29%20Antibody%20Screening%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Human Leukocyte Antigen (HLA) Antibody Screening Market Growth Factors: What’s Supporting Expansion?

    The increasing rates of organ transplantation are anticipated to drive the future expansion of the HLA antibody screening market. Organ transplantation rates quantify the total number of organ transplant operations performed within a specific population over a period, typically expressed annually or per million people. This surge in transplantation procedures is largely a result of the escalating burden of chronic and end-stage diseases; as more patients progress to organ failure, the demand for organ replacement therapies concurrently rises. HLA antibody screening significantly contributes to higher organ transplantation success by ensuring superior donor-recipient compatibility before surgery, thereby reducing the likelihood of immune-mediated rejection. This process minimizes graft loss and complications, enhances long-term transplant outcomes, and facilitates more effective utilization of available donor organs. For example, in January 2025, the Health Resources and Services Administration, a US-based agency of the Department of Health and Human Services, reported that lung transplants saw the highest proportional increase between 2023 and 2024, climbing from 3,026 procedures to 3,340, which indicates a 10.4% growth. Thus, the escalating organ transplantation rates are propelling the growth of the HLA antibody screening market.

    Human Leukocyte Antigen (HLA) Antibody Screening Market Segmentation And Category Overview

    The human leukocyte antigen (HLA) antibody screening market covered in this report is segmented –

    1) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Luminex, Other Technologies

    2) By Product Type: Reagents And Kits, Instruments, Software

    3) By Target Class: Human Leukocyte Antigen Class I Antibodies, Human Leukocyte Antigen Class II Antibodies, Non- Human Leukocyte Antigen Antibodies

    4) By Application: Pre-Transplant Screening, Post-Transplant Monitoring, Transfusion Medicine, Research Applications

    5) By End-User: Hospitals And Transplant Centers, Diagnostic Laboratories, Research Institutes, Other End-Users

    Subsegments:

    1) By Enzyme Linked Immunosorbent Assay: Direct Enzyme Linked Immunosorbent Assay, Indirect Enzyme Linked Immunosorbent Assay, Sandwich Enzyme Linked Immunosorbent Assay, Competitive Enzyme Linked Immunosorbent Assay

    2) By Flow Cytometry: Conventional Flow Cytometry, Bead Based Flow Cytometry, Imaging Flow Cytometry, High Throughput Flow Cytometry

    3) By Luminex: Single Antigen Luminex Assay, Multi Antigen Luminex Assay, Bead Based Multiplex Luminex Assay, Custom Luminex Panels

    4) By Other Technologies: Western Blotting, Radioimmunoassay, Complement Dependent Cytotoxicity Assay, Microarray Based Assay

    Human Leukocyte Antigen (HLA) Antibody Screening Market Industry Trends: What’s Reshaping Demand?

    Major companies in the HLA antibody screening market are concentrating on developing advanced HLA research instruments to enhance the accuracy of immune checkpoint research, antibody validation, and assay development. These next-generation HLA research tools integrate innovative recombinant reagents, multiplexed analytical platforms, and high-resolution molecular technologies, which enable precise profiling of HLA molecules and how they interact with antibodies. For example, in November 2025, HLA Protein Technologies, a US-based biotechnology company, unveiled its sHLA-G Monomer and Tetramer Portfolio, an advanced HLA research tool that supports high-fidelity checkpoint biology studies, target validation, and assay development. This portfolio offers structurally validated recombinant HLA-G reagents, optimized for immune receptor interaction studies, thereby facilitating improved characterization of HLA-associated antibodies and driving progress in transplant immunology, oncology, and immune tolerance research applications.

    Human Leukocyte Antigen (HLA) Antibody Screening Market Competitive Analysis Of Leading Industry Participants

    Major companies operating in the human leukocyte antigen (HLA) antibody screening market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S A, Beckman Coulter Inc., Bio Rad Laboratories Inc., QIAGEN N V, Takara Bio Inc., Fujirebio Inc., CareDx Inc., Histogenetics LLC, Creative Biolabs Inc., Biofortuna Ltd., Stanford Blood Center, GenDx B V, Omixon Biocomputing Ltd., BAG Diagnostics GmbH, Scisco Genetics Inc., TBG Diagnostics Ltd., American Red Cross.

    View The Full Human Leukocyte Antigen (HLA) Antibody Screening Market Report:

    https://thebusinessresearchcompany.com/report/human-leukocyte-antigen-hla-antibody-screening-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Human Leukocyte Antigen (HLA) Antibody Screening Market Geographic Distribution And Regional Opportunities

    North America was the largest region in the human leukocyte antigen (HLA) antibody screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) antibody screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Human Leukocyte Antigen (HLA) Antibody Screening Market Expansion Supported By Rising Organ Transplantation Rates And Demand For Improved Graft Survival

    Human Leukocyte Antigen (HLA) Antibody Screening Market Expansion Supported By Rising Organ Transplantation Rates And Demand For Improved Graft Survival

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Estimated Market Size Of The Human Leukocyte Antigen (HLA) Antibody Screening Market In 2026, And How Will Its Value Evolve By 2030?

    The human leukocyte antigen (HLA) antibody screening market size has shown significant growth in recent years. It is projected to increase from $0.98 billion in 2025 to $1.06 billion in 2026, registering a compound annual growth rate (CAGR) of 8.4%. This historical growth can be attributed to a rising number of organ transplant procedures, increasing incidence of end-stage organ failure, growing awareness of transplant rejection risks, expansion of transfusion medicine practices, and technological advancements in immunoassay platforms.

    The human leukocyte antigen (HLA) antibody screening market size is anticipated to undergo significant expansion in the coming years. This market is projected to reach $1.47 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. The expansion over the forecast period is primarily driven by factors such as an escalating demand for precision transplant matching, the increased adoption of multiplex bead-based assays, growing investments in transplant immunology research, the broadening of transplant programs in emerging markets, and technological advancements in automated HLA antibody screening systems. Noteworthy trends during this period include the rising acceptance of single antigen bead assays for enhanced sensitivity, a growing requirement for comprehensive pre-transplant immunological risk assessment, the expanded application of high-throughput flow cytometry in HLA screening, the development of post-transplant antibody monitoring protocols, and the increasing standardization of HLA antibody detection methods.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample_request?id=12617629&type=smp&name=Human%20Leukocyte%20Antigen%20%28HLA%29%20Antibody%20Screening%20Market%20Report%202026

    What Leading Drivers Are Supporting The Human Leukocyte Antigen (HLA) Antibody Screening Market Expansion?

    The HLA antibody screening market is anticipated to expand due to increasing rates of organ transplantation. These rates indicate the frequency of organ transplant operations conducted within a defined population and timeframe, typically measured annually or per million individuals. The escalation in transplant procedures is primarily a consequence of the growing prevalence of chronic and terminal illnesses; as more patients develop organ failure, the need for organ replacement therapies consequently rises. HLA antibody screening plays a crucial role in enhancing the success of organ transplantation by facilitating superior donor-recipient compatibility pre-surgery, thereby diminishing the likelihood of immune-mediated rejection, which in turn reduces graft loss and associated complications, improves long-term transplant results, and enables more efficient utilization of available donor organs. For example, the Health Resources and Services Administration, a US Department of Health and Human Services agency, stated in January 2025 that lung transplants experienced the most significant proportional increase between 2023 and 2024, climbing from 3,026 procedures to 3,340, marking a 10.4% rise. Consequently, the increasing volume of organ transplants is propelling the HLA antibody screening market’s growth.

    What Are The Key Segment Divisions In The Human Leukocyte Antigen (HLA) Antibody Screening Market Segment Structure?

    The human leukocyte antigen (HLA) antibody screening market covered in this report is segmented –

    1) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Luminex, Other Technologies

    2) By Product Type: Reagents And Kits, Instruments, Software

    3) By Target Class: Human Leukocyte Antigen Class I Antibodies, Human Leukocyte Antigen Class II Antibodies, Non- Human Leukocyte Antigen Antibodies

    4) By Application: Pre-Transplant Screening, Post-Transplant Monitoring, Transfusion Medicine, Research Applications

    5) By End-User: Hospitals And Transplant Centers, Diagnostic Laboratories, Research Institutes, Other End-Users

    Subsegments:

    1) By Enzyme Linked Immunosorbent Assay: Direct Enzyme Linked Immunosorbent Assay, Indirect Enzyme Linked Immunosorbent Assay, Sandwich Enzyme Linked Immunosorbent Assay, Competitive Enzyme Linked Immunosorbent Assay

    2) By Flow Cytometry: Conventional Flow Cytometry, Bead Based Flow Cytometry, Imaging Flow Cytometry, High Throughput Flow Cytometry

    3) By Luminex: Single Antigen Luminex Assay, Multi Antigen Luminex Assay, Bead Based Multiplex Luminex Assay, Custom Luminex Panels

    4) By Other Technologies: Western Blotting, Radioimmunoassay, Complement Dependent Cytotoxicity Assay, Microarray Based Assay

    What Trends Are Shaping The Future Of The Human Leukocyte Antigen (HLA) Antibody Screening Market?

    Leading companies operating within the HLA antibody screening market are prioritizing the development of next-generation HLA research tools to enhance the precision of immune checkpoint research, antibody validation, and assay development. These advanced HLA research tools encompass innovative recombinant reagents, multiplexed analytical platforms, and high-resolution molecular technologies, which facilitate accurate profiling of HLA molecules and their antibody interactions. For example, in November 2025, HLA Protein Technologies, a US-based biotechnology company, unveiled its sHLA-G Monomer and Tetramer Portfolio. This particular next-generation HLA research tool is designed to support high-fidelity checkpoint biology studies, target validation, and assay development. The portfolio offers structurally validated recombinant HLA-G reagents, specifically optimized for immune receptor interaction studies, thereby promoting improved characterization of HLA-associated antibodies and advancing applications in transplant immunology, oncology, and immune tolerance research.

    Which Organizations Are Engaged In The Human Leukocyte Antigen (HLA) Antibody Screening Market?

    Major companies operating in the human leukocyte antigen (HLA) antibody screening market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S A, Beckman Coulter Inc., Bio Rad Laboratories Inc., QIAGEN N V, Takara Bio Inc., Fujirebio Inc., CareDx Inc., Histogenetics LLC, Creative Biolabs Inc., Biofortuna Ltd., Stanford Blood Center, GenDx B V, Omixon Biocomputing Ltd., BAG Diagnostics GmbH, Scisco Genetics Inc., TBG Diagnostics Ltd., American Red Cross.

    Get The Full Human Leukocyte Antigen (HLA) Antibody Screening Market Report:

    https://www.thebusinessresearchcompany.com/report/human-leukocyte-antigen-hla-antibody-screening-market-report

    Where Is The Human Leukocyte Antigen (HLA) Antibody Screening Market Most Concentrated Geographically?

    North America was the largest region in the human leukocyte antigen (HLA) antibody screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) antibody screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Human Leukocyte Antigen (HLA) Antibody Screening Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/Customise?id=12617629&name=Human%20Leukocyte%20Antigen%20%28HLA%29%20Antibody%20Screening%20Market%20Report%202026&type=smp

    Browse Through More Reports Similar to the Global Human Leukocyte Antigen (HLA) Antibody Screening Market 2026, By The Business Research Company

    pruritus therapeutic market report 2026

    https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

    genomic urine testing market report 2026

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    ocular genetic diagnostic market report 2026

    https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model